New Drugs from Marine Organisms in Alzheimer’s Disease
Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder. Current approved drugs may only ameliorate symptoms in a restricted number of patients and for a restricted period of time. Currently, there is a translational research challenge into identifying the new effective drugs and the...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2015-12-01
|
| Series: | Marine Drugs |
| Subjects: | |
| Online Access: | http://www.mdpi.com/1660-3397/14/1/5 |
| _version_ | 1811187573825994752 |
|---|---|
| author | Patrizia Russo Aliaksei Kisialiou Palma Lamonaca Rossana Moroni Giulia Prinzi Massimo Fini |
| author_facet | Patrizia Russo Aliaksei Kisialiou Palma Lamonaca Rossana Moroni Giulia Prinzi Massimo Fini |
| author_sort | Patrizia Russo |
| collection | DOAJ |
| description | Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder. Current approved drugs may only ameliorate symptoms in a restricted number of patients and for a restricted period of time. Currently, there is a translational research challenge into identifying the new effective drugs and their respective new therapeutic targets in AD and other neurodegenerative disorders. In this review, selected examples of marine-derived compounds in neurodegeneration, specifically in AD field are reported. The emphasis has been done on compounds and their possible relevant biological activities. The proposed drug development paradigm and current hypotheses should be accurately investigated in the future of AD therapy directions although taking into account successful examples of such approach represented by Cytarabine, Trabectedin, Eribulin and Ziconotide. We review a complexity of the translational research for such a development of new therapies for AD. Bryostatin is a prominent candidate for the therapy of AD and other types of dementia in humans. |
| first_indexed | 2024-04-11T14:04:40Z |
| format | Article |
| id | doaj.art-3cea933ecdd04ece9eaef6b0bde26a88 |
| institution | Directory Open Access Journal |
| issn | 1660-3397 |
| language | English |
| last_indexed | 2024-04-11T14:04:40Z |
| publishDate | 2015-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Marine Drugs |
| spelling | doaj.art-3cea933ecdd04ece9eaef6b0bde26a882022-12-22T04:19:55ZengMDPI AGMarine Drugs1660-33972015-12-01141510.3390/md14010005md14010005New Drugs from Marine Organisms in Alzheimer’s DiseasePatrizia Russo0Aliaksei Kisialiou1Palma Lamonaca2Rossana Moroni3Giulia Prinzi4Massimo Fini5Clinical and Molecular Epidemiology Division, IRCCS “San RaffaelePisana” Via di Valcannuta, 247, RomeI-00166, ItalyClinical and Molecular Epidemiology Division, IRCCS “San RaffaelePisana” Via di Valcannuta, 247, RomeI-00166, ItalyClinical and Molecular Epidemiology Division, IRCCS “San RaffaelePisana” Via di Valcannuta, 247, RomeI-00166, ItalyClinical and Molecular Epidemiology Division, IRCCS “San RaffaelePisana” Via di Valcannuta, 247, RomeI-00166, ItalyClinical and Molecular Epidemiology Division, IRCCS “San RaffaelePisana” Via di Valcannuta, 247, RomeI-00166, ItalyScientific Direction, IRCCS “San RaffaelePisana” Via di Valcannuta, 247, Rome I-00166, ItalyAlzheimer’s disease (AD) is a multifactorial neurodegenerative disorder. Current approved drugs may only ameliorate symptoms in a restricted number of patients and for a restricted period of time. Currently, there is a translational research challenge into identifying the new effective drugs and their respective new therapeutic targets in AD and other neurodegenerative disorders. In this review, selected examples of marine-derived compounds in neurodegeneration, specifically in AD field are reported. The emphasis has been done on compounds and their possible relevant biological activities. The proposed drug development paradigm and current hypotheses should be accurately investigated in the future of AD therapy directions although taking into account successful examples of such approach represented by Cytarabine, Trabectedin, Eribulin and Ziconotide. We review a complexity of the translational research for such a development of new therapies for AD. Bryostatin is a prominent candidate for the therapy of AD and other types of dementia in humans.http://www.mdpi.com/1660-3397/14/1/5marine drugsAlzheimer’s diseasemechanisms of activityclinical/preclinical studiesbryostatinnew drugs |
| spellingShingle | Patrizia Russo Aliaksei Kisialiou Palma Lamonaca Rossana Moroni Giulia Prinzi Massimo Fini New Drugs from Marine Organisms in Alzheimer’s Disease Marine Drugs marine drugs Alzheimer’s disease mechanisms of activity clinical/preclinical studies bryostatin new drugs |
| title | New Drugs from Marine Organisms in Alzheimer’s Disease |
| title_full | New Drugs from Marine Organisms in Alzheimer’s Disease |
| title_fullStr | New Drugs from Marine Organisms in Alzheimer’s Disease |
| title_full_unstemmed | New Drugs from Marine Organisms in Alzheimer’s Disease |
| title_short | New Drugs from Marine Organisms in Alzheimer’s Disease |
| title_sort | new drugs from marine organisms in alzheimer s disease |
| topic | marine drugs Alzheimer’s disease mechanisms of activity clinical/preclinical studies bryostatin new drugs |
| url | http://www.mdpi.com/1660-3397/14/1/5 |
| work_keys_str_mv | AT patriziarusso newdrugsfrommarineorganismsinalzheimersdisease AT aliakseikisialiou newdrugsfrommarineorganismsinalzheimersdisease AT palmalamonaca newdrugsfrommarineorganismsinalzheimersdisease AT rossanamoroni newdrugsfrommarineorganismsinalzheimersdisease AT giuliaprinzi newdrugsfrommarineorganismsinalzheimersdisease AT massimofini newdrugsfrommarineorganismsinalzheimersdisease |